Taking schizophrenia medication when you don’t have schizophrenia will still produce real, measurable effects on your brain and body. These drugs, called antipsychotics, work by blocking dopamine receptors, and that mechanism doesn’t switch off just because your dopamine system is functioning normally. The result is a range of side effects, from immediate sedation and weight gain to longer-term risks like involuntary movement disorders, with very little upside if psychosis isn’t what’s being treated.
What These Drugs Do to a Typical Brain
Antipsychotics were designed to quiet an overactive dopamine system, which is a hallmark of psychosis. They do this primarily by blocking a specific type of dopamine receptor (called D2). In someone with schizophrenia, this blockade dials down hallucinations and delusions. In someone whose dopamine signaling is already balanced, the same blockade creates a deficit where none existed before.
Your brain doesn’t passively accept this change. When dopamine receptors are consistently blocked, the brain compensates by producing more of them and making the remaining ones more sensitive. This process, called dopamine supersensitivity, means your brain essentially recalibrates itself around the drug. Over time, this creates a cycle: the medication becomes less effective at the same dose, requiring more of it, which triggers further receptor changes. For someone without schizophrenia, this is particularly concerning because you’re forcing your brain into an artificial dependency loop it never needed.
What You’d Feel Right Away
The most noticeable immediate effect is heavy sedation. Many antipsychotics block histamine receptors (the same ones targeted by sleep aids), which can make you feel profoundly drowsy, foggy, and slow. This isn’t a pleasant, relaxed feeling for most people. It’s closer to being unable to think clearly or stay awake.
Older antipsychotics (sometimes called “typical” or first-generation) are particularly likely to cause movement-related side effects almost immediately. These include muscle stiffness, restlessness that makes it impossible to sit still, tremors, and a general loss of fine motor control. These sensations are unpleasant enough that even patients who need the medication frequently stop taking it. Newer antipsychotics cause fewer of these movement problems but trade them for a different set of issues, particularly metabolic ones.
Weight Gain and Metabolic Changes
One of the most well-documented effects of antipsychotic use, regardless of diagnosis, is significant weight gain. A study in healthy volunteers found that olanzapine (one of the more commonly prescribed antipsychotics) increased calorie intake by about 345 extra calories per day and caused 2.6 kilograms of weight gain in just two weeks. In longer trials, olanzapine produced weight gain approaching 1 kilogram per month, with some patients gaining roughly 12 kilograms over a year.
The metabolic damage goes beyond the number on the scale. Antipsychotics can raise blood sugar levels even in the early stages of use. Some do this by increasing glucagon, a hormone that tells the liver to release more glucose, and by making liver cells resistant to insulin. In animal studies, a single dose was enough to trigger measurable insulin resistance. Over time, this can progress toward type 2 diabetes.
Cholesterol and blood fat levels are also affected. People taking antipsychotics face roughly 2.8 times the risk of high cholesterol and 2.3 times the risk of high triglycerides compared to those not on these medications. The worst offenders for metabolic effects are olanzapine and clozapine, while aripiprazole, lurasidone, and ziprasidone carry minimal metabolic risk. But even “lower-risk” antipsychotics are not metabolically neutral.
Tardive Dyskinesia: A Movement Disorder That Can Be Permanent
The most serious long-term risk of taking antipsychotics without medical need is tardive dyskinesia, a movement disorder characterized by repetitive, involuntary movements, often of the face, tongue, and jaw. It can also affect the limbs and trunk. The critical thing to understand about tardive dyskinesia is that it can persist even after the drug is stopped, sometimes permanently.
Among people on long-term antipsychotic therapy, 20% to 25% develop tardive dyskinesia. The risk climbs steeply with time: in older adults, cumulative rates reach about 25% after one year, 34% after two years, and 53% after three years. Older adults and women face the highest risk, and first-generation antipsychotics are more likely to cause it than newer ones. But newer antipsychotics are not risk-free. Risperidone, for example, carries a notably higher tardive dyskinesia risk than other second-generation options because of how strongly it blocks dopamine receptors.
Hormonal Effects
Several antipsychotics raise levels of prolactin, a hormone normally involved in milk production. Elevated prolactin can cause breast tenderness or enlargement in both men and women, menstrual irregularities, sexual dysfunction, and reduced bone density over time. Risperidone is the most common culprit, producing prolactin elevations comparable to older antipsychotics. Other newer options like aripiprazole have little to no effect on prolactin.
Why Doctors Still Prescribe Them for Other Conditions
Antipsychotics are prescribed for a surprisingly wide range of non-schizophrenia conditions, which is part of why this question comes up. Approved uses include bipolar depression, treatment-resistant major depression (usually as an add-on to an antidepressant), and irritability associated with autism. Off-label, they’re used for anxiety, insomnia, PTSD, OCD, eating disorders, personality disorders, Tourette’s syndrome, and severe agitation in elderly patients with dementia.
In these situations, the prescribing logic is that the benefits outweigh the risks for that specific person. Doses tend to be lower than what’s used for schizophrenia, and the choice of drug often targets the side effect profile. Someone prescribed a low dose of quetiapine for insomnia, for instance, is getting a very different risk exposure than someone on a high dose of olanzapine for psychosis. But the metabolic and neurological risks don’t disappear at lower doses. They’re reduced, not eliminated.
The Withdrawal Problem
Stopping antipsychotics after your brain has adapted to them is its own challenge. Because of the dopamine supersensitivity that develops during treatment, abruptly stopping can trigger rebound symptoms: insomnia, nausea, anxiety, and in some cases, psychotic-like experiences that the person never had before starting the drug. This doesn’t mean the medication “revealed” an underlying condition. It means the brain’s dopamine system has been artificially recalibrated and needs time to normalize. Tapering off slowly under medical supervision reduces these withdrawal effects, but the process can take weeks or months.
For someone who never had a psychiatric condition requiring these drugs, this creates an unfortunate scenario: a medication taken without clear need produces brain changes that then make it difficult to stop. The longer the exposure, the more entrenched these changes become.